Abstract
Persistent neuroinflammation is now recognized as a chief pathological component of practically all neurodegenerative diseases. Neuroinflammation in the central nervous system (CNS), is accompanied with immune responses of glial cells. Glial cells respond to pathological stimuli through antigen presentation, and cytokine and chemokine signaling. Therefore, limiting CNS inflammation represents prospective therapeutic approach in diseases like Alzheimer’s, amyotrophic lateral sclerosis, Parkinson’s, ischemia, various psychiatric disorders and Multiple sclerosis (MS). As a complex disease, MS is characterized by neuroinflamation, demyelination and sequential axonal loss. Due to unknown etiology and the heterogeneous presentation of the disease, MS is hard to treat and the search for potential therapeutics is wide and meticulous. However, finding a proper antineuroinflammatory drug may bring an advance in selecting novel treatment regimens of ample of neurodegenerative diseases and neurological disorders. The present review gives the overview of the existing and potential therapies in MS, aimed to modulate neuroinflammation and ensure neuroprotection.
Keywords: MS, EAE, neuroinflammation, therapies.
Current Pharmaceutical Design
Title:Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Volume: 23 Issue: 5
Author(s): Ivana Bjelobaba, Danijela Savic and Irena Lavrnja
Affiliation:
Keywords: MS, EAE, neuroinflammation, therapies.
Abstract: Persistent neuroinflammation is now recognized as a chief pathological component of practically all neurodegenerative diseases. Neuroinflammation in the central nervous system (CNS), is accompanied with immune responses of glial cells. Glial cells respond to pathological stimuli through antigen presentation, and cytokine and chemokine signaling. Therefore, limiting CNS inflammation represents prospective therapeutic approach in diseases like Alzheimer’s, amyotrophic lateral sclerosis, Parkinson’s, ischemia, various psychiatric disorders and Multiple sclerosis (MS). As a complex disease, MS is characterized by neuroinflamation, demyelination and sequential axonal loss. Due to unknown etiology and the heterogeneous presentation of the disease, MS is hard to treat and the search for potential therapeutics is wide and meticulous. However, finding a proper antineuroinflammatory drug may bring an advance in selecting novel treatment regimens of ample of neurodegenerative diseases and neurological disorders. The present review gives the overview of the existing and potential therapies in MS, aimed to modulate neuroinflammation and ensure neuroprotection.
Export Options
About this article
Cite this article as:
Bjelobaba Ivana, Savic Danijela and Lavrnja Irena, Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612822666161214153108
DOI https://dx.doi.org/10.2174/1381612822666161214153108 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Full Kinetics and a Mechanistic Investigation of the Synthesis of Tetrahydrobenzo[ b]pyrans in the Presence of Sodium Acetate as a Catalyst by a One-pot Three-component Reaction
Letters in Organic Chemistry The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update
Current Neuropharmacology Stability, Disposition, and Penetration of Catalytic Antioxidants Mn-Porphyrin and Mn-Salen and of Methylprednisolone in Spinal Cord Injury
Central Nervous System Agents in Medicinal Chemistry Commentary: Histaminergic Drugs Could be Novel Targets for Neuroprotection in CNS Disorders
CNS & Neurological Disorders - Drug Targets Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation
CNS & Neurological Disorders - Drug Targets Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy Stem Cell-Derived Motor Neurons: Applications and Challenges in Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy Editorial [Hot topic: New Therapeutic Strategies for Treatment of Neurodegenerative Diseases (Executive Editor: Aleksey G. Kazantsev)]
Current Pharmaceutical Design Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Current Alzheimer Research Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Biomarkers for Alzheimer’s Disease
Current Alzheimer Research Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Phosphorylation-Dephosphorylation Imbalance of Cytoskeletal Associated Proteins in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued)